Advancing Care and Outcomes for African American Patients With Multiple Sclerosis

Author(s):
Annette F. Okai, MD¹; Annette M. Howard, MD²; Mitzi J. Williams, MD³; Justine D. Brink, DO, MPH⁴; Chiayi Chen, RN, PhD⁵; Tamela L. Stuchiner, MA⁶; Elizabeth Baraban, MPH, PhD⁶; Grace Jeong, PhD⁶; Stanley L. Cohan, MD, PhD⁴

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.
Corresponding Author:
Annette F. Okai, aokaimd@outlook.com

Affiliation Information for All Authors: 1. North Texas Institute of Neurology and Headache, 5150 Warren Pkwy, Plano, TX 75024, USA; 2. Multiple Sclerosis Institute of Texas, 6655 Travis St Ste 590, Houston, TX 77030, USA; 3. Joi Life Wellness Multiple Sclerosis Neurology Center, 767 Concord Rd SE, Smyrna, GA 30082, USA; 4. Providence Brain and Spine Institute, Providence St, Vincent Medical Center, 9155 SW Barnes Rd, Suite 317, Portland, OR 97225, USA; 5. Alphabet Health, New York, NY, USA

Equal Author Contribution:

Contributions:
Annette F. Okai: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design
Annette M. Howard: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design
Mitzi J. Williams: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design
Justine D. Brink: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design
Chiayi Chen: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design
Tamela L. Stuchiner: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design
Elizabeth Baraban: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design
Grace Jeong: Drafting/revision of the manuscript for content, including medical writing for content
Stanley L. Cohan: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design
Figure Count:
2

Table Count:
0

Search Terms:
[ 41 ] Multiple sclerosis, [ 345 ] Equity, Diversity, and Inclusion (EDI), [ 355 ] Health disparities, African Americans, Disease burden

Acknowledgment:
Editorial support was provided by Akua Adu-Boahene, MD, MPH, of Alphabet Health. This manuscript was developed in accordance with Good Publication Practice (GPP3) guidelines. Authors had full control of the content and made the final decision on all aspects of this publication.

Study Funding:
The costs for infrastructure support, website development, and distribution of printed materials for the NAAMSR have been solely provided by the Providence Brain and Spine Institute. Medical writing and editorial support for the development of this manuscript was funded by Novartis Pharmaceuticals Corporation.

Disclosures:
A.F. Okai has received speaking and consulting fees from Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Novartis, and Sanofi Genzyme, and research support from Alexion, Biogen, EMD Serono, Roche Genentech, Novartis, Sanofi Genzyme, and TG Therapeutics; A.M. Howard has received consulting fees from and served on advisory boards for Sanofi Genzyme, and Bristol Myers Squibb, and has received speaker honoraria from Sanofi Genzyme, EMD Serono, and Bristol Myers Squibb; M.J. Williams has received consulting/speaking fees from Biogen, EMD Serono, Genentech, Novartis, Sanofi Genzyme, Abbvie, Alexion, Janssen and Bristol Myers Squibb.
and research support from Biogen Idec, Novartis and Genentech; J.D. Brink has received speaker honoraria from Teva and served on an advisory board for Biogen; C. Chen has no conflict of interest to report; T.L. Stuchiner has no conflict of interest to report.; E. Baraban has no conflict of interest to report; G. Jeong is an employee of Alphabet Health; S.L. Cohan has served on advisory boards or steering committees for AbbVie, Biogen, EMD Serono, Novartis, Roche Genentech, and Sanofi Genzyme, has received research support from AbbVie, Adamas, Biogen, Novartis, Sanofi Genzyme, MedDay, Opexa, Teva and Roche Genentech, and has received speaker honoraria from Biogen, Bristol Myer Squibb, Novartis, Sanofi Genzyme, and Roche Genentech.

Preprint DOI:

Received Date:
2021-10-29 00:00:00.000

Accepted Date:
2022-04-11 00:00:00.000

Handling Editor Statement:
Abstract

Multiple sclerosis (MS) has historically been underdiagnosed and undertreated among African Americans. Recent evidence suggests that African Americans with MS have a different clinical presentation, increased disease incidence and burden, and worsened long-term outcomes versus their White counterparts. Due to limited data available for African Americans in MS clinical trials, it is difficult to make informed, generalizable conclusions about the natural history, prognosis, and therapeutic response in this population. In this narrative review, we highlight the nature and magnitude of the health disparities experienced by African Americans with MS and underscore the pressing need to increase knowledge about and understanding of MS disease manifestations in this group. Additionally, we describe the mission and objectives of the recently established National African Americans with Multiple Sclerosis Registry (NAAMSR), which is intended to be a platform to advance the care of African Americans with MS and address health disparities they may experience.

Keywords

Multiple sclerosis; African Americans; health disparities; disease burden
Introduction

Multiple sclerosis (MS) is an autoimmune demyelinating disorder of multifactorial etiology, involving a complex interplay of genetics, environmental factors, and sex. Social determinants of health, including ethnic/racial disparities and inequities, socioeconomic status, healthcare access, and health literacy, can also impact MS care and treatment outcomes. The current understanding of the impact of race and ethnicity on MS incidence, pathogenesis, disease course, and treatment response is limited, which may be attributable to the underrepresentation of minority populations in clinical trials.

Historically, MS has been considered to be more common particularly in White people of northern European ancestry, versus other ethnic groups. However, there is increasing evidence of the importance of the disease in minority populations. As will be discussed in this review, higher MS risk and incidence, more severe disease at diagnosis, more aggressive disease course, and limited treatment response have been suggested particularly in the Black or African American population, compared with other racial groups in the US. Despite the unique challenges and unmet needs of Black or African American people living with MS (AAwMS), clinicians have limited ability to draw informed, generalizable conclusions about the natural history, prognosis, and therapeutic response in this population given the paucity of available clinical data. Findings of a PubMed literature search (performed in February 2022) highlight the paucity of and need for published literature/data in this patient population: a search of ‘black african american multiple sclerosis’ found 49 results in the last 5 years, and 69 results in the last 10 years; whereas a search of ‘multiple sclerosis united states’ found 3965 results in the last 5 years, and 7141 results in the last 10 years.

In this narrative review, we provide an overview of the limited clinical data published in the literature on the nature and magnitude of MS disease experienced by Black/AAwMS and underscore the pressing need to increase knowledge about and understanding of MS in this patient population. Additionally, we describe the mission and objectives of the recently established National African Americans with Multiple Sclerosis Registry (NAAMSR), which is intended as a platform to advance the care of AAwMS and address the health disparities they experience.
Disparities in clinical outcomes and healthcare access

The incidence of MS in the US has historically been thought to be lower in Black or African American people than in White individuals; however, there is increasing evidence to the contrary. A retrospective study of a multiethnic US cohort (N=486, >9 million person-years of observation) newly diagnosed with MS between 2008 and 2010 found the incidence of MS per 100,000 person-years to be highest in the Black subgroup (regardless of ethnicity) (10.2) when compared with the non-Hispanic White (6.9), Hispanic White (2.9), and Asian or Pacific Islander (1.4) subgroups. MS risk in this study was found to be 47% higher in the Black subgroup (vs non-Hispanic White). This difference was driven by a higher risk in Black women than non-Hispanic White women (risk ratio 1.59, 95% CI 1.27–1.99; \( p=0.0005 \)), whereas MS risk in men was similar in both racial groups (risk ratio 1.04, 95% CI 0.67–1.57; \( p=0.87 \)).

A recent retrospective analysis (2010–2016) of a multiethnic US cohort (N=3286) reported similar findings of highest age-adjusted MS incidence in non-Hispanic Black patients compared with non-Hispanic White, Hispanic, and other minority groups, with highest prevalence in non-Hispanic Black women. MS prevalence in African Americans has been shown to be higher than native Africans with no European ancestry, and lower than those of European ancestry, possibly due to the effects of genetic admixture. There is substantial variation in the proportion of genomes of European and African ancestry in African Americans in the US. Of note, race and ethnicity are patient-reported in the majority of studies evaluating differences in clinical outcomes described below.

In addition to higher MS risk and incidence, Black/AAwMS suffer from earlier mortality compared with MS patients in other minority groups in the US. Based on findings of an analysis of 16 years of data (1999-2015) from the CDC’s Data for Epidemiological Research system, non-Hispanic Black people with MS were found to have the highest mortality rate in patients <55 years of age relative to non-Hispanic White, Asian or Pacific Islander, American Indian or Alaska Native, and Hispanic people with MS. Mortality rates were highest for non-Hispanic Black patients in the 55–64 year-old age group, compared to 65–74 years for non-Hispanic White patients. These data demonstrating higher mortality risk at a younger age in Black people with MS compared with their White counterparts suggest variability in the burden of disease by race/ethnicity in the US that may be attributed to differences in comorbidities, access to care, and MS disease progression in these patient populations.
Black/AAwMS may experience more severe disease at baseline, with a significantly greater frequency of multifocal involvement at initial clinical presentation. \(^{14}\) They may also experience higher Expanded Disability Status Scale (EDSS) scores versus their White counterparts at diagnosis (2.9 vs 1.8; \(p=0.0002\)) and through ≥5 years follow up (5.6 vs 4.1; \(p=0.0001\)). \(^{15}\) Moreover, Black/AAwMS may experience faster clinical progression and poorer clinical outcomes than their White counterparts. In a retrospective cohort study of 375 AAwMS, African American patients (mean disease duration of 9.8 years) had a significantly shorter median time to ambulation with a cane (16 vs 22 years; \(p<0.0001\)) and wheelchair dependency (30 vs 38 years; \(p=0.05\)), a 1.67-fold greater risk of requiring a cane for ambulation (\(p<0.001\)), and a trend toward a shorter median conversion time to secondary progressive MS (18 vs 21 years; \(p=0.051\)) versus White Americans (n=427; mean disease duration of 11.4 years). The faster disability accumulation observed among African Americans was thought to be partly attributable to their older age at disease onset (33.7 vs 31.1 years; \(p=0.0001\)), \(^{14}\) a factor which has been associated with a poorer prognosis. \(^{16}\) The lower frequency of the HLA-DRB1*15 allele is thought to contribute to the later age of disease onset seen in AAwMS. \(^{17}\)

In an analysis of patient- and physician-reported data of 419 Black/AAwMS and 5,809 non-Hispanic White Americans living with MS (of similar age at disease onset and diagnosis) in the New York State Multiple Sclerosis Consortium database, median Multiple Sclerosis Severity Scale (MSSS) score (an algorithm relating MS disability to disease duration) was higher in Black/AAwMS (6.0 vs 4.8; \(p=0.0001\)), suggesting a more rapidly disabling disease course. Black/AAwMS were overrepresented in the two most severe MSSS categories (41.5% vs 29.3%) and underrepresented in the two least severe categories (23.4% vs 35.4%; overall \(p<0.001\)). Additionally, they had a 2.6-fold higher prevalence of ‘malignant’ (or rapidly progressing) MS (7.3% vs 2.9%; \(p<0.001\)). \(^{17, 18}\)

Magnetic resonance imaging (MRI) and optical coherence tomography studies suggest that AAwMS experience neurodegeneration and loss of brain and retinal tissue that is different from and more rapid than their White counterparts. \(^{19-23}\) AAwMS experience atrophy of grey matter (–0.9%/year vs –0.5%; \(p=0.02\)), white matter (–0.7%/year vs –0.3%; \(p=0.04\)) and nuclear thalamic tissue (–1.5%/year vs –0.7%/year; \(p=0.02\)) at rates twice that of White patients of similar age and disease duration. Atrophy rates of retinal nerve fiber layer (–1.1% vs –0.8%; \(p=0.02\)) and ganglion cell inner plexiform layer (0.7%/year vs –0.4%/year; \(p=0.01\)) were faster in African American patients. \(^{24}\) Findings of these imaging studies corroborate the more rapid disease progression observed in African Americans as described above. These variations in MS
disease expression observed among African Americans may be influenced by genetic factors. African origin within the HLA locus has been implicated in disability progression, and genotyping of the HLA-DRB1*15 allele suggests that the increased incidence of opticospinal disease among African Americans may be related to the lower frequency of the allele in this population (37.6% vs 53.3% in White Americans living with MS). African Americans have a significantly higher risk of neuromyelitis optica spectrum disorder, with earlier onset and more severe attacks, compared with White and Asian patients.

Black/AAwMS may be less responsive to certain disease-modifying therapies (DMTs) than their White counterparts, which may adversely impact their clinical outcomes. A retrospective chart review of 67 self-defined African Americans and 67 White Americans living with MS receiving DMTs (interferons, glatiramer acetate, and natalizumab) reported a greater median EDSS difference from baseline through follow-up for African Americans versus White patients (1.0 vs 0; p<0.001) despite a shorter mean disease duration (7.1 vs 15.1 years; p<0.001) and similar age at diagnosis (34.3 vs 36.9; p=0.13). Although the number of patients studied was small, the results suggest a poorer response to at least some DMTs in AAwMS. These findings of increased disability over a shorter disease duration in African Americans are in line with the trend suggested by a post hoc analysis of the EVIDENCE study comparing the response to interferon β-1a treatment in African American (n=36) and White American (n=616) patients. In EVIDENCE, African American patients had more new T2-weighted MS lesions on MRI (2.00 vs 1.10; p=0.04) and were less likely to remain relapse free (47% vs 57%; p=0.24) at 48 weeks. Again, these findings are limited by the small sample size of African American patients included in the study (5.5% of 652 patients). Subgroup analyses of patients from the pivotal Phase 3 trials of natalizumab (AFFIRM, SENTINEL) and ocrelizumab (OPERA I/II), and Phase 4 studies of fingolimod (PREFERMS) and dimethyl fumarate (ESTEEM), suggest that these therapies can provide clinical and radiographic benefits for Black/African American patients. Though promising, these analyses were hindered by the limited representation of Black/African American patients in the trials (AFFIRM, n=10 of 942 [1.1%]; SENTINEL, n=39 of 1,171 [3.3%]; OPERA I/II, n=72 of 1,656 [4.3%]; PREFERMS, n=141 of 875 [16.1%]; ESTEEM, n=187 of 5084 [3.7%]), highlighting the urgent need for more well-controlled data in this group.

In addition to underrepresentation in clinical trials, social determinants of health can contribute to health disparities and inequities in MS care and clinical outcomes. A recent review noted a paucity of published literature on the impact of social determinants of
health on clinical outcomes and racial/ethnic inequities in MS and related disorders such as neuromyelitis optica spectrum disorder for Black or African American patients in the US, despite their higher risk of disease and mortality compared with White individuals. Lower socioeconomic status (e.g., education level, income) was associated with greater health disparities, including higher disease burden and more cognitive/psychiatric symptoms. The reasons for these disparities and inequities are likely multifactorial (Figure 1), including but not limited to gaps between need of and access to medical care and supportive services, societal/cultural constructs (e.g., systemic/unconscious bias and racism), and lack of culturally competent care. Further observational, epidemiological, and long-term longitudinal studies (taking into consideration both the genetic ancestry and social determinants of health) will be important for developing optimal treatment strategies for the Black and African American MS patient population, with increased efforts to better understand and help alleviate the racial/ethnic disparities and inequities in clinical care in the US.
Further strategies to address and combat health inequities for African Americans with MS

As described above, AAwMS may experience increased incidence and disease burden, and worsened long-term outcomes compared with their White counterparts. To help address the specific unmet needs of this patient population, there is a compelling need to develop a robust cohort of AAwMS to increase knowledge about and understanding of the disease in this population.

A platform that was created in response to this need is the National African Americans with MS Registry (NAAMSR; www.naamsr.org), which was launched on September 1, 2020. The objectives and design of the registry are summarized in Figure 2. The NAAMSR aims to: (1) create reliable estimates of the number and geographical distribution of AAwMS in the US; (2) identify barriers and improve access to MS care; and (3) improve care for AAwMS through patient and healthcare provider education. The registry was founded by neurologists who specialize in MS care, including leading African American MS neurologists located in different regions of the US. The registry also aims to increase opportunities for interested African Americans to participate in clinical trials, so that the therapeutic needs of AAwMS are better understood through future research and drug development.

The registry aims to enroll 20,000 to 30,000 self-identifying AAwMS across urban, suburban, and rural communities in the US. Those interested in participating will register on the naamsr.org website. They will then be emailed a link to complete a baseline survey. Participants will be sent the link to complete the survey annually. Participation in the registry is voluntary and collected information is fully protected and will only be utilized for research purposes. Unlike other databases which rely mainly on physician-reported data, the NAAMSR questionnaire collects participant-reported information on topics including: demographic and socioeconomic status, timing of symptom onset and diagnosis, MS pattern, use of DMTs, quality of life, disability status, comorbidities, and access to care. The primary measures the NAAMSR hopes to address are: (1) the impact of social determinants of health on access to care, timeliness of diagnosis, DMT initiation, and long-term outcomes; (2) the potential effect of racial identity on disease pattern and severity; and (3) the relationship between disease severity and medication efficacy. Participants can also opt to receive a lay-friendly newsletter circulated regularly to provide new and relevant educational information on MS and treatment options, increase awareness of clinical trials and other research efforts, and help bridge gaps in health literacy.
Outreach efforts to reach both healthcare providers and patients to aid with registry recruitment are ongoing, and have included personal communications to academic and private institutions, publicity via social media, podcasts, the National MS Society website, various programming (e.g. National MS Society Black Experience Summit, MS Association of America’s African American Advisory Board), continuing medical education channels, and medical conferences/meetings. Educational outreach to patients and their care team will also be prioritized. The registry also seeks to engage in collaborations/partnerships that advance the care and well-being of AAwMS.

Increased understanding and awareness of the clinical impact of various genetic, environmental, societal, and cultural factors is needed to improve and optimize disease management and treatment outcomes for AAwMS. Through educational efforts targeting patients and their care team, the cultivation of patient trust, and by encouraging participation in research and clinical trials, the medical community can better serve the unmet needs of this vulnerable MS patient population.
# Appendix 1 Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annette F. Okai, MD</td>
<td>Plano, TX</td>
<td>Design and concept; drafted the manuscript; and significant revisions</td>
</tr>
<tr>
<td>Annette M. Howard, MD</td>
<td>Houston, TX</td>
<td>Design and concept; drafted the manuscript; and significant revisions</td>
</tr>
<tr>
<td>Mitzi Joi Williams, MD</td>
<td>Smyrna, GA</td>
<td>Design and concept; drafted the manuscript; and significant revisions</td>
</tr>
<tr>
<td>Justine D. Brink, DO, MPH</td>
<td>Portland, OR</td>
<td>Implementation; design and concept; drafted the manuscript; and significant revisions</td>
</tr>
<tr>
<td>Chiayi Chen, RN, PhD</td>
<td>Portland, OR</td>
<td>Implementation; design and concept; drafted the manuscript; and significant revisions</td>
</tr>
<tr>
<td>Tamela L. Stuchiner, MA</td>
<td>Portland, OR</td>
<td>Implementation; design and concept; drafted the manuscript; and significant revisions</td>
</tr>
<tr>
<td>Elizabeth Baraban, MPH, PhD</td>
<td>Portland, OR</td>
<td>Implementation; design and concept; drafted the manuscript; and significant revisions</td>
</tr>
<tr>
<td>Grace Jeong, PhD</td>
<td>New York, NY</td>
<td>Drafted the manuscript and significant revisions</td>
</tr>
<tr>
<td>Stanley L. Cohan, MD, PhD</td>
<td>Portland, OR</td>
<td>Implementation; design and concept; drafted the manuscript; and significant revisions</td>
</tr>
</tbody>
</table>
References


Figure captions

Figure 1. Social determinants influencing inequities in MS care and outcomes. From Okai A et al. National African American Multiple Sclerosis Registry: Advancing Equitable Care and Outcomes for African Americans with Multiple Sclerosis. Poster presented at the American Academy of Neurology (AAN) Virtual Annual Meeting, April 17-21, 2021.

Figure 2. The National African Americans with Multiple Sclerosis Registry (NAAMSR). From Okai A et al. National African American Multiple Sclerosis Registry: Advancing Equitable Care and Outcomes for African Americans with Multiple Sclerosis. Poster presented at the American Academy of Neurology (AAN) Virtual Annual Meeting, April 17-21, 2021.

The NAAMSR (www.naamsr.org) was launched on September 1, 2020

Primary objectives
1. Expand evidence-based knowledge of MS and its management in African Americans
2. Educate AAwMS and increase their opportunities for clinical trial participation
3. Engage in research beneficial to AAwMS

Registry design:
- Target enrollment: 20,000–30,000 registrants in urban, suburban, and rural communities
- Self-identifying AAwMS are being recruited via brochure distribution at health care facilities, and print, broadcast, internet, and social media outreach
- Registrants are sent an extensive questionnaire via email after registering on the NAAMSR website, and annually thereafter
  - Questionnaire topics include demographic and socioeconomic status, timing of symptom onset and diagnosis, MS pattern, use of DMTs, quality of life, disability status, and access to care

Primary measures:
- The impact of social determinants of health on access to care, timeliness of diagnosis, DMT initiation, and long-term outcomes
- The potential effect of racial identity on disease pattern and severity
- The relationship between disease severity and medication efficacy
Advancing Care and Outcomes for African American Patients With Multiple Sclerosis
Annette F. Okai, Annette M. Howard, Mitzi J. Williams, et al.
*Neurology* published online April 25, 2022
DOI 10.1212/WNL.0000000000200791

This information is current as of April 25, 2022

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://n.neurology.org/content/early/2022/04/25/WNL.0000000000200791.full">http://n.neurology.org/content/early/2022/04/25/WNL.0000000000200791.full</a></th>
</tr>
</thead>
</table>
| Subspecialty Collections      | This article, along with others on similar topics, appears in the following collection(s):  
Health disparities [http://n.neurology.org/cgi/collection/health_disparities](http://n.neurology.org/cgi/collection/health_disparities)  
Inclusion, Diversity, Equity, Anti-racism, and Social Justice (IDEAS) [http://n.neurology.org/cgi/collection/all_equity_diversity_and_inclusion](http://n.neurology.org/cgi/collection/all_equity_diversity_and_inclusion)  
Multiple sclerosis [http://n.neurology.org/cgi/collection/multiple_sclerosis](http://n.neurology.org/cgi/collection/multiple_sclerosis) |
| Permissions & Licensing       | Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: [http://www.neurology.org/about/about_the_journal#permissions](http://www.neurology.org/about/about_the_journal#permissions) |
| Reprints                      | Information about ordering reprints can be found online: [http://n.neurology.org/subscribers/advertise](http://n.neurology.org/subscribers/advertise) |